Seeking Alpha

Seeking Alpha Portfolio App for iPad

6,815 people get LLY articles and Market Currents by email alert.

Get email alerts on LLY »

LLY

Eli Lilly and Company

5/24/2013, 7:45 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 9:07 AM Eli Lilly (LLY) slips 1% premarket after saying a study of enzastaurin "did not show a statistically significant increase compared to placebo in disease-free survival" for patients with diffuse large B-cell lymphoma. LLY will discontinue development and take a $30M Q2 R&D expense. FY13 guidance unchanged. (PR) 2 Comments [Healthcare]
Tuesday, May 7, 6:20 AM Eli Lilly (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.60%. For shareholders of record May 16. Payable June 10. Ex-div date May 14. (PR) Comment! [Dividends]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Wednesday, April 24, 3:28 PM In what seems to be a trend in companies reporting today, Eli Lilly (LLY -3.6%) dips after posting a mixed Q1, beating on a per share basis but coming up short on revenue. Net earnings rose 53% Y/Y, primarily from a gain from selling rights to a diabetes drug, but a slowdown in its Elanco animal-health kept overall revenue flat. LLY has been cultivating sales growth in its animal-health division as a strategy for getting through the wave of patent expirations, but sales in the unit rose only 2% for the quarter, compared to 21% growth during the same prior-year period. Comment! [Healthcare, Earnings, On the Move]
Wednesday, April 24, 6:31 AM Eli Lilly (LLY): Q1 EPS of $1.14 beats by $0.08. Revenue of $5.60B (flat% Y/Y) misses by $0.06B. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Wednesday, April 17, 8:37 AM Eli Lilly (LLY) agrees to acquire two imaging agents from Siemens (SI) that are designed to show brain deposits of tau, a protein that's linked with Alzheimer's disease and cell death. The acquisition of the agents, which are radiopharmaceutical tracers used with PET scans, add to Eli's Amyvid tracer that can detect beta amyloid, another protein linked with Alzheimer's. Financial details of the deal weren't disclosed. (PR) Comment! [Healthcare, M&A]
Tuesday, April 16, 1:38 PM Eli Lilly (LLY +1.3%) says a once-weekly treatment for type 2 diabetes (dulaglutide) met its primary efficacy endpoints in Phase III clinical trials. LLY, which could certainly use a marketed GLP-1 drug, plans to submit dulaglutide for regulatory approval this year. Comment! [Healthcare]
Thursday, April 11, 6:27 PM More on Eli Lilly (LLY): Most of the workers affected by the layoffs are part of the company’s U.S. bio-medicines division, as six of it’s blockbuster products lose their patent exclusivity over the next four years, thus allowing low-priced generic competitors to enter the market and grab away over $13B in potential business. Shares +0.4% AH. Comment! [Healthcare]
Thursday, April 11, 5:23 PM More on Eli Lilly (LLY): The drug maker acknowledged earlier that it plans to restructure its sales force and cut personnel, but still hasn't confirmed recent reports on the number of layoffs. The company says it's making the move because of changing market dynamics, and to compensate for the loss of two key patents for Cymbalta and Evista. 2 Comments [Healthcare]
Thursday, April 11, 5:03 PM Dow Jones reporting Eli Lilly (LLY) to lay off around 30% of its U.S. sales force, which accounts for about 1,000 positions. 14 Comments [Healthcare, Breaking News, Top Stories]
Wednesday, April 10, 1:37 PM Jefferies raises its price targets on big pharma names Pfizer (PFE +2.6%) ($33), Merck (MRK +2.7%) ($48), Johnson & Johnson (JNJ +0.7%) ($85), Eli Lilly (LLY +1.4%) ($44), Bristol-Myers Squibb (BMY +0.5%) ($45), AbbVie (ABBV +1.2%) ($50), and Abbot Laboratories (ABT +1.1%) ($42). "We remain positive on pharmaceuticals," Jefferies says, "valuation is attractive for most stocks." 6 Comments [Healthcare]
Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
Tuesday, April 2, 7:05 PM Citi strategists tweak the criteria for their top dividend-paying stock picks, lowering the standard for dividend yield while adding a new filter for dividend momentum “to give more emphasis on dividend safety and growth." The full list: MO, AEP, T, AVB, BMY, ED, D, DD, DUK, INTC, KMB, KRFT, LLY, MCD, MRK, MSFT, NU, NOC, OXY, PFE, PM, RTN, SRE, SO, SYY, XEL. 5 Comments [Quick Ideas]
Tuesday, April 2, 9:32 AM Eli Lilly (LLY +0.1%) is working closely with Indianapolis on a plan to invest $260M on its insulin manufacturing operations in the city and on other ancillary projects, including a $40M product-inspection center. The investment would add to a $140M scheme that Eli Lilly announced in November. (PR) Comment! [Healthcare]

1
2
3
4
5
6
...
15
Next Page